Development asset linked to Arcturus Therapeutics in public FDA and regional records.
pharma · COVID-19 · Cystic Fibrosis · ARCT
Arcturus Therapeutics
Arcturus Therapeutics Holdings
Arcturus Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
10285 Science Center Dr, San Diego, California 92121, US HQ
2013 Founded
157 Employees
Public company Type
ARCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10285 Science Center Dr, San Diego, California 92121, US
- Founded
- 2013
- Employees
- 157
- Programs
- 13
- Drugs
- 7
- Patents
- 55
Arcturus Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Arcturus Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Arcturus Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Arcturus Therapeutics in public FDA and regional records.
-
Development asset linked to Arcturus Therapeutics in public FDA and regional records.
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Arcturus Therapeutics's portfolio.
-
Development asset linked to Arcturus Therapeutics in public FDA and regional records.
-
Development asset linked to Arcturus Therapeutics in public FDA and regional records.